TABLE 6.
Vitrification of buffalo matured oocytes using various protocols and devices
| Equilibration solution | Vitrification solution | Devices | Survival rate | BL rate | Reference |
|---|---|---|---|---|---|
|
SSV: 4% EG 12–15 min CLV: 7.5% EG + 7.5% DMSO 3 min |
SSV: 35% EG + 5% PVP + 0.4 M trehalose 25–30 s CLV: 16.5% EG + 16.5% DMSO 25 s |
SSV, CLV |
SSV + cumulus cell: 95.8% SSV ‐ cumulus cell: 84.6% CLV + cumulus cell: 98.5% CLV ‐ cumulus cell: 81.4% |
SSV + cumulus cell: 1.5% SSV cumulus cell: 7% CLV + cumulus cell: 0% CLV cumulus cell: 2.8% |
Gasparrini et al., 2007 |
|
SSV: 4% EG 5–10 min Straw: 4% EG 5–10 min |
SSV: 35% EG + 5% PVP + 0.4 M Trehalose 25–30 s Straw: 40% EG + 5% PVP + 0.4 M Trehalose 1 min + LN2 vapor 3 min |
SSV, straw |
SSV: 89.3% straw: 81.8% |
SSV: 13.6% straw: 5.5% |
Boonkusol et al., 2007 |
|
7.5% EG + 7.5% DMSO 4 min 7 min 10 min |
15% EG + 15% DMSO 1 min | Cryotop |
MII/vitrified: 66%–71% enucleated/vitrified: 69%–71% |
MII/vitrified: 4 min: 10% 7 min: 9% 10 min: 8% enucleated/vitrified: 4 min: 9% 7 min: 7% 10 min: 7% |
Muenthaisong et al., 2007 |
|
a. 10%, 25%, 40% EG each 1 min b. 10%, 25%, 40% DMSO each 1 min c. 10% EG + 10% DMSO 1 min d: 10% EG + 10% PROH 1 min |
a: 40% EG 1 min b: 40% DMSO 1 min c: 20% EG + 20% DMSO 1 min d: 20% EG + 20% PROH 1 min |
Straw |
a. 85% b. 92% c. 96% d. 95% |
a. 1.66% b. 2.29% c. 5.49% d. 2.74% |
Gautam et al., 2008 |
|
a. 7.5% EG + 7.5% DMSO 3 min b. 10% EG + 10% DMSO 3 min |
a. 16.5% EG + 16.5% DMSO 20–25 s b. 20% EG + 20% DMSO 20–25 s |
Cryotop |
a. 84% b. 85.6% |
a. 6.4% b. 7.8% |
Attanasio, Boccia, et al., 2010 |
| 10% EG + 10% DMSO 3 min | 20% EG + 20% DMSO 20–25 s | Cryotop | 86%–92% | 1.4%–8.0% | Attanasio, De Rosa, et al., 2010 |
| 10% EG + 10% DMSO 1 min | 20% EG + 20% DMSO 30 or 45 s | Microdrop |
30 s: 96% 45 s: 91% |
30 s: 11% 45 s: 7% |
Liang, Phermthai, et al., 2011 |
|
VA: 10% EG + 10% DMSO 1 min VB: 4% EG 12–15 min |
VA: 20% EG + 20% DMSO 30 s VB: 35% EG + 50 mg/ml PVP 30 s |
Microdrop Cryotop |
VA + microdrop: 93% VA + Cryotop: 97% VB + microdrop: 79% VB + Cryotop: 81% |
VA + microdrop: 8% VA + Cryotop: 10% VB + microdrop: 5% VB + Cryotop: 11% |
Liang, Rakwongrit, et al., 2012 |
| 7.5% EG + 7.5% DMSO 5 min | 15% EG + 15% DMSO + 0.5 M sucrose |
Cryotop SSV |
CTP cumulus (+): 85.93% CTP cumulus (−): 82.67% SSV cumulus (+):87.74% SSV cumulus (−): 81.38% |
CTP cumulus (+): 10.46% CTP cumulus (−): 4.29% SSV cumulus (+):12.41% SSV cumulus (−): 3.00% |
Atabay et al., 2013 |
|
10% DMSO and 10% EG 1 min. (with pre‐treatment with CB 8 μg/ml for 30 min) |
20% DMSO, 20% EG and 0.5 M sucrose 30 s | Cryotop |
2nd polar body formation: CB + Cryotop:51.16% Cryotop: 43.88% |
17.08% 10.21% |
Wang et al., 2016 |
| 10% EG + 10% DMSO | 20%EG + 20% DMSO | Cryotop |
0 mg/ml L‐carnitine 96% 0.3 mg/ml L‐carnitine 97% 0.6 mg/ml L‐carnitine 97% 1.2 mg/ml L‐carnitine 96% Fresh control 100% |
0 mg/ml L‐carnitine 4% 0.3 mg/ml L‐carnitine 4% 0.6 mg/ml L‐carnitine 8% 1.2 mg/ml L‐carnitine 8% Fresh control 19% |
Liang et al., 2020 |
Abbreviations: CB, cytochalasin B; CLV, cryoloop vitrification; DMSO, dimethyl sulfoxide; EG, ethylene glycol; LN2, liquid nitrogen; MII, metaphase II stage; PROH, propylene glycol (1, 2‐propanediol); SSV, solid surface vitrification; VA, vitrification A solution; VB, vitrification B solutions.